{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"28.3","value":"23.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"OS was defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Tucatinib 300 mg PO BID on Days 1 to 21 of each 21-day cycle. Trastuzumab 8 mg/kg by IV infusion on Day 1 of Cycle 1 and 6 mg/kg on Day 1 of each subsequent cycle until PD, death, withdrawal of consent, study closure, or alternative therapy.","id":"OG000","title":"Tucatinib+Trastuzumab (Cohorts A+B)"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set included all participants who were enrolled and received any amount of study treatment and had HER2+ tumors as defined by one or more protocol required local tests. Data for cohort A and B was combined as prespecified in SAP.","reportingStatus":"POSTED","timeFrame":"Up to 71.8 months","title":"Overall Survival (OS) in Pooled Cohorts A+B","type":"SECONDARY","unitOfMeasure":"Months"}